Clinical trial · Observational
Exploration on the Value of MRD Based on ctDNA Detection in Predicting Recurrence of Resected Non-small Cell Lung Cancer
Exploration on the Value of Molecular Residual Disease Based on Circulating Tumor DNA Detection in Predicting Recurrence of Resected Non-small Cell Lung Cancer
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Based on the unique patented MONOD and Methyl Titan methylation sequencing technology on lung cancer tissue and blood samples, a lung cancer MRD monitoring panel is designed. The panel is used to detect molecular residual disease of stage IB-IIIB non-small cell lung cancer patients underwent radical surgery, explore personalized analysis models, and conduct research on recurrence monitoring for non-small cell lung cancer patients.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Non-small Cell Lung Cancer | Lung Non-Small Cell Carcinoma | ALIAS | 0.90 |
Interventions
Interventions (0)
Data not yet available
Design
Arms and outcomes
Arms (0)
[]Primary outcomes (1)
- measure
- 2-year recurrence-free survival rate
- timeFrame
- Up to 24 months
- description
- Recurrence-free survival means the time from the date of surgery to the first recorded date of disease recurrence or patient death, whichever occurs earlier. 2-year recurrence-free survival rate means the rate of patients survive without recurrence for 2 years or more.
Secondary outcomes (1)
- measure
- Median recurrence-free survival
- timeFrame
- up to 60 months
- description
- Recurrence-free survival means the time from the date of surgery to the first recorded date of disease recurrence or patient death, whichever occurs earlier. Median recurrence-free survival means the median value of recurrence-free survival.
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: 1. Age ≥ 18 years old, regardless of gender; 2. Patients with pathological diagnosis of non-small cell lung cancer and clinical staging of stage IB-IIIB; 3. Able to undergo radical surgical treatment; 4. Physical condition score (ECOG) ≤1; 5. The expected survival time exceeds 24 months; 6. Volunteer to participate in this study and sign an informed consent form. Exclusion Criteria: 1. Individuals with a history of other malignant tumors within 5 years; 2. Those who have undergone neoadjuvant therapy before surgery; 3. Postoperative incision margin R1 or incision margin R2; 4. Those who have undergone a blood transfusion within 2 weeks before the surgery; 5. Individuals with systemic inflammatory response syndrome; 6. Those with serious diseases of important organs such as the heart, lungs, kidneys, and brain; 7. Participants in other clinical trials within the past 30 days and have taken investigational drugs; 8. Due to various reasons, sampling cannot be completed, samples do not meet the requirements, or baseline samples (preoperative and postoperative plasma samples, tumor tissue samples) are incomplete; 9. Researchers believe that it is not appropriate to participate in this experiment.
References
Publications (0)
Data not yet available